Unique ID issued by UMIN | UMIN000035711 |
---|---|
Receipt number | R000040680 |
Scientific Title | Evaluation of the efficacy of sofosbuvir and velpatasvir in HCV-infected Japanese patients with decompensated cirrhosis: a prospective study in real life settings. |
Date of disclosure of the study information | 2019/03/01 |
Last modified on | 2019/01/29 21:19:35 |
Evaluation of the efficacy of sofosbuvir and velpatasvir in HCV-infected Japanese patients with decompensated cirrhosis: a prospective study in real life settings.
The efficacy of sofosbuvir and velpatasvir in HCV-infected Japanese patients with decompensated cirrhosis.
Evaluation of the efficacy of sofosbuvir and velpatasvir in HCV-infected Japanese patients with decompensated cirrhosis: a prospective study in real life settings.
The efficacy of sofosbuvir and velpatasvir in HCV-infected Japanese patients with decompensated cirrhosis.
Japan |
decompensated cirrhotic patients with hepatitis C virus
Hepato-biliary-pancreatic medicine |
Others
YES
Identifying the predictive factors of virological response in sofosbuvir and velpatasvir treatment.
Safety
Confirmatory
Not applicable
sustained virological response (SVR) at 12 weeks after the end of treatment (EOT)
SVR at 24 weeks after the EOT
incidence rate of adverse events durig treatment
the change of Child-Pugh score at 12 and 24 weeks after the EOT from baseline
Observational
20 | years-old | <= |
Not applicable |
Male and Female
decompensated cirrhotic patients with HCV RNA
Child-Pugh A
100
1st name | |
Middle name | |
Last name | Fumitaka Suzuki |
Toranomon Hospital
hepatology
2-2-2, Toranomon, Minato-ku, Tokyo
03-3588-1111
fumitakas@toranomon.gr.jp
1st name | |
Middle name | |
Last name | Hitomi Sezaki |
Toranomon Hospital
hepatology
2-2-2, Toranomon, Minato-ku, Tokyo
03-3588-1111
hitomis@mx1.harmonix.ne.jp
Toranomon Hospital
Japan Agency for Medical Research and Development
Japanese Governmental office
Japan
NO
虎の門病院(東京)
2019 | Year | 03 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2019 | Year | 01 | Month | 28 | Day |
2019 | Year | 03 | Month | 01 | Day |
combination tablet of sofosbuvir/velpatasvir(400mg/100mg) one tablet once daily for 12 weeks.
Evaluating the association with baseline characteristics (viral factors and host factors) and virological response.
2019 | Year | 01 | Month | 29 | Day |
2019 | Year | 01 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040680
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |